Hospital
Peacehealth
Peacehealth was paid $41.28M by Medicaid between Jan 2018 and Dec 2024, across 153 billing codes. Its largest line is 99285, emergency room visit (most serious) — 29% of everything it billed.
33Billing provider infoPEACEHEALTH
SEDRO WOOLLEY, WA 98284
SEDRO WOOLLEY, WA 98284
33aNPI1144664954assigned 04/23/2013
33bProvider typeCritical Access Hospital
28Total paid$41.28M
24GClaims330,736
24DCodes billed153
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#2 of 30
Median peer was paid$9.10M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,292 | $5.64M | |
| 2019 | 41,060 | $6.09M | |
| 2020 | 42,739 | $5.17M | |
| 2021 | 52,191 | $5.62M | |
| 2022 | 57,954 | $7.01M | |
| 2023 | 54,311 | $5.94M | |
| 2024incomplete | 42,189 | $5.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 29% | 13,142 | 11,869 | $11.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 11,160 | 10,289 | $6.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 14,027 | 13,235 | $4.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.2% | 3,914 | 3,728 | $3.79M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 3,029 | 2,833 | $1.15M |
| 80053 | Comprehensive metabolic panel | 2.0% | 19,694 | 16,752 | $809K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,745 | 3,636 | $658K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,006 | 964 | $637K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 532 | 501 | $579K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 8,264 | 7,519 | $576K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 10,342 | 9,112 | $566K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 5,238 | 4,179 | $551K |
141 more codes
| 84484 | 1.3% | 10,811 | $523K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 8,855 | $464K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,408 | $409K |
| G0378 | Hospital observation service, per hour | <1% | 403 | $373K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 645 | $361K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,967 | $360K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 697 | $329K |
| 87631 | <1% | 3,678 | $326K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,189 | $320K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,346 | $306K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,576 | $255K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,192 | $238K |
| 84703 | <1% | 5,591 | $224K | |
| 83605 | <1% | 5,351 | $212K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,213 | $205K |
| 83690 | <1% | 8,878 | $203K | |
| 83880 | <1% | 2,898 | $202K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,682 | $173K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,280 | $168K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,807 | $151K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,985 | $146K |
| 96376 | <1% | 3,241 | $143K | |
| 85379 | <1% | 2,644 | $140K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,515 | $137K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,688 | $129K |
| 83735 | <1% | 5,565 | $112K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 268 | $107K |
| 81001 | <1% | 11,284 | $107K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,879 | $106K |
| 80305 | <1% | 4,140 | $105K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 620 | $85K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,049 | $84K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,855 | $80K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,592 | $80K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,450 | $79K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 338 | $77K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,705 | $74K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,120 | $73K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,757 | $71K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 338 | $65K |
| 87040 | <1% | 946 | $60K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,941 | $60K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,088 | $59K |
| 73562 | <1% | 449 | $57K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,877 | $55K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,631 | $54K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 340 | $52K |
| 73610 | <1% | 439 | $52K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,146 | $49K |
| 82550 | <1% | 1,801 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,298 | $46K |
| 85610 | <1% | 3,228 | $46K | |
| 82803 | <1% | 1,358 | $45K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,770 | $42K |
| 87430 | <1% | 1,309 | $35K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,481 | $33K |
| 71250 | <1% | 75 | $32K | |
| 73110 | <1% | 189 | $32K | |
| 96367 | <1% | 618 | $30K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 921 | $30K |
| 87081 | <1% | 1,082 | $28K | |
| 73630 | <1% | 269 | $27K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,110 | $26K |
| 87186 | <1% | 1,038 | $26K | |
| 85730 | <1% | 1,089 | $24K | |
| 73130 | <1% | 161 | $21K | |
| 97161 | <1% | 276 | $20K | |
| 73030 | <1% | 171 | $18K | |
| 86140 | <1% | 950 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 118 | $17K |
| 82553 | <1% | 396 | $17K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 421 | $14K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 37 | $12K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 64 | $12K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 298 | $11K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 755 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 561 | $10K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 176 | $9K |
| 12001 | <1% | 71 | $9K | |
| 87147 | <1% | 266 | $8K | |
| 85027 | <1% | 468 | $8K | |
| 93971 | <1% | 38 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 65 | $8K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 509 | $7K |
| 80306 | <1% | 698 | $7K | |
| 97162 | <1% | 70 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 768 | $6K |
| 87077 | <1% | 150 | $6K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 128 | $6K |
| 81003 | <1% | 478 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 80 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 164 | $5K |
| 96368 | <1% | 266 | $5K | |
| 85652 | <1% | 612 | $4K | |
| 73502 | <1% | 39 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 53 | $3K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $3K |
| 84460 | <1% | 177 | $3K | |
| 84450 | <1% | 177 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 214 | $3K |
| 72100 | <1% | 25 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 100 | $3K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 222 | $3K |
| 87088 | <1% | 129 | $3K | |
| 73140 | <1% | 26 | $3K | |
| 94060 | <1% | 12 | $3K | |
| 74022 | <1% | 16 | $3K | |
| 90715 | <1% | 229 | $2K | |
| 76801 | <1% | 14 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 42 | $2K |
| 84702 | <1% | 69 | $2K | |
| 87205 | <1% | 107 | $2K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 72 | $2K |
| 10060 | <1% | 13 | $2K | |
| 80076 | <1% | 94 | $2K | |
| 82140 | <1% | 48 | $2K | |
| 73080 | <1% | 13 | $2K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 94 | $2K |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 70 | $2K |
| 84439 | <1% | 99 | $2K | |
| 87070 | <1% | 45 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 87 | $1K |
| 87581 | <1% | 62 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 119 | $1K |
| 94729 | <1% | 13 | $832.03 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 20 | $815.18 |
| 94726 | <1% | 12 | $777.27 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 977 | $621.34 |
| 82075 | <1% | 18 | $586.55 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 25 | $536.50 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 12 | $527.49 |
| 97035 | <1% | 22 | $328.09 | |
| 87486 | <1% | 16 | $195.88 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 12 | $129.65 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 43 | $28.84 |
| A9270 | Non-covered item or service | 0% | 2,580 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 12 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 23 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 110 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMONTALVO, DARRIN (EVP CHIEF FINANCIAL /GROWTH OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Peacehealth | Bellingham, WA | $26.14M |
| Peacehealth | Vancouver, WA | $13.58M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.